Suchergebnisse - "Machiels, J P"

PubPharm (136)

1

Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Honoré, N. | van Marcke, C. | Galot, R. | +12

CommentIn: Ann Oncol. 2023 Dec;34(12):1080-1081. - PMID 38072511

2

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence

enthalten in: Oral oncology | 2023

von Harrington, K. | Cohen, E. | Soulières, D. | +13

3

Corrigendum to 'Salivary gland cancer : ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022

enthalten in: ESMO open | 2023

von van Herpen, C. | Vander Poorten, V. | Skalova, A. | +14

ErratumFor: ESMO Open. 2022 Dec;7(6):100602. - PMID 36567082

4

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck : KESTREL, a randomized, open-label, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Psyrri, A. | Fayette, J. | Harrington, K. | +26

5

ESMO-EURACAN Clinical Practice Guideline update for nasopharyngeal carcinoma : adjuvant therapy and first-line treatment of recurrent/metastatic disease

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Bossi, P. | Chan, A. | Even, C. | +2

6

Salivary gland cancer : ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up

enthalten in: ESMO open | 2022

von van Herpen, C. | Vander Poorten, V. | Skalova, A. | +14

ErratumIn: ESMO Open. 2023 Oct;8(5):101630. - PMID 37625197

7

Isatuximab plus atezolizumab in patients with advanced solid tumors : results from a phase I/II, open-label, multicenter study

enthalten in: ESMO open | 2022

von Simonelli, M. | Garralda, E. | Eskens, F. | +29

8

Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

enthalten in: ESMO open | 2021

von Keam, B. | Machiels, J. | Kim, H. | +22

9

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19 : a cohort study

enthalten in: BMC cancer | 2021

von van Marcke, C. | Honoré, N. | van der Elst, A. | +23

10

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

enthalten in: BMC cancer | 2021

von van Marcke, C. | Honoré, N. | van der Elst, A. | +23

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]